Evidence map›Paper›PMID 39296258›Full record

ArticleACS pharmacology & translational science2024

Bidirectional Effect of Long-Term Δ

Andras Bilkei-Gorzo, Britta Schurmann, Marion Schneider, Michael Kraemer, Prakash Nidadavolu, Eva C Beins, Christa E Müller, Mona Dvir-Ginzberg, Andreas Zimmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andras Bilkei-GorzoInstitute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn 53125, Germany.ORCID https://orcid.org/0000-0002-6805-0472
Britta SchurmannInstitute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn 53125, Germany.
Marion SchneiderPharmaceutical Institute, University of Bonn, Bonn 53121, Germany.
Michael KraemerInstitute of Forensic Medicine, Medical Faculty, University of Bonn, Bonn 53111, Germany.
Prakash NidadavoluInstitute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn 53125, Germany.
Eva C BeinsInstitute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn 53125, Germany.
Christa E MüllerPharmaceutical Institute, University of Bonn, Bonn 53121, Germany.ORCID https://orcid.org/0000-0002-0013-6624
Mona Dvir-GinzbergInstitute of BioMedical and Oral Research, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Andreas ZimmerInstitute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn 53125, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain aging is associated with cognitive decline, reduced synaptic plasticity, and altered metabolism. The activity of mechanistic target of rapamycin (mTOR) has a major impact on aging by regulating cellular metabolism. Although reduced mTOR signaling has a general antiaging effect, it can negatively affect the aging brain by reducing synaptogenesis and thus cognitive functions. Increased mTOR activity facilitates aging and is responsible for the amnestic effect of the cannabinoid receptor 1 agonist Δ

Identifiers

PMID39296258
PMCPMC11406684

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.